← Back to Search

Retinoid

Benzoyl Peroxide vs Adapalene for Molluscum Contagiosum

Phase 3
Waitlist Available
Led By Jason Hirshburg, MD
Research Sponsored by University of Oklahoma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Must not have
Patients who decline to assent for participation.
Patients who have received prior treatment for molluscum contagiosum.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

Summary

This trial tests two treatments for children with molluscum contagiosum. One treatment uses benzoyl peroxide to kill germs and dry out bumps. The other uses adapalene to reduce swelling and prevent new bumps. The goal is to see which treatment clears the skin better over a few months.

Who is the study for?
This trial is for children aged 1 to 14 with molluscum contagiosum who haven't been treated before. It's open to those whose parents want treatment and can consent, but not for kids who've had reactions to topical retinoids or benzoyl peroxide, among others.
What is being tested?
The study compares the effectiveness of two creams: benzoyl peroxide (10%) and adapalene gel (0.1%) in treating molluscum contagiosum. Kids will use one of these treatments daily as tolerated, aiming for complete lesion clearance at 12 weeks.
What are the potential side effects?
Possible side effects include skin irritation, dryness, redness from benzoyl peroxide; adapalene may cause similar reactions plus sensitivity to sunlight.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not agree to participate in this study.
Select...
I have been treated for molluscum contagiosum before.
Select...
My caregiver does not speak English.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Complete clearance at 12 weeks

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Benzoyl peroxideExperimental Treatment1 Intervention
topical benzoyl peroxide 10% (vehicle choice per patient preference) applied 1-2x daily as tolerated until complete clearance or 12 week follow up
Group II: AdapaleneActive Control1 Intervention
adapalene 0.1% gel applied 1-2x daily as tolerated until complete clearance or 12 week follow up
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Benzoyl peroxide
2021
Completed Phase 4
~2840

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Benzoyl Peroxide works by reducing bacterial load and promoting the shedding of the outer skin layer, which helps in clearing Molluscum Contagiosum lesions. Adapalene, a retinoid, modulates cell differentiation and keratinization, normalizing skin cell turnover and reducing lesion formation. These mechanisms are crucial for patients as they explain how these treatments help manage and clear the infection effectively.
Treatment of molluscum contagiosum in males with an analog of imiquimod 1% in cream: a placebo-controlled, double-blind study.[Molluscum contagiosum: treatment with pulsed dye laser].

Find a Location

Who is running the clinical trial?

University of OklahomaLead Sponsor
466 Previous Clinical Trials
91,223 Total Patients Enrolled
Jason Hirshburg, MDPrincipal InvestigatorUniversity of Oklahoma

Media Library

Adapalene Gel (Retinoid) Clinical Trial Eligibility Overview. Trial Name: NCT05536882 — Phase 3
Molluscum Contagiosum Research Study Groups: Adapalene, Benzoyl peroxide
Molluscum Contagiosum Clinical Trial 2023: Adapalene Gel Highlights & Side Effects. Trial Name: NCT05536882 — Phase 3
Adapalene Gel (Retinoid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05536882 — Phase 3
~0 spots leftby Oct 2025